Skip to main content

Table 2 Correlation between mutational status and resistance to anti-EGFR moAb therapy

From: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

Mutant genes

Responders (CR + PR + SD)a vs non-responders

 

Total responders

Total non-responders

Mutant responders

Mutant non-responders

P-valueb

KRAS c

37

28

3

8

0.045

NRAS

37

28

1

1

0.999

BRAF

37

28

1

4

0.156

PI3KCA

37

28

2

4

0.389

FBXW7

37

28

1

5

0.077

SMAD4

37

28

1

4

0.156

NRAS/BRAF/PIK3CA d

37

28

3

8

0.045

NRAS/BRAF/PIK3CA/FBXW7 d

37

28

4

11

0.016

NRAS/BRAF/PIK3CA/FBXW7/SMAD4 d

37

28

4

13

0.002

  1. a CR complete response, PR partial response, SD stable disease
  2. b P-value from Fisher's exact test
  3. cPreviously undetected mutations
  4. dSamples with mutations in at least one of the indicated genes